Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

[1]  C. Caldas,et al.  Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[2]  C. Nicolazzo,et al.  Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[3]  J. Lemonnier,et al.  UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Paik,et al.  Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 , 2015 .

[5]  E. Perez,et al.  Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) , 2015 .

[6]  M. Cristofanilli,et al.  IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model. , 2015, Journal of the National Cancer Institute. Monographs.

[7]  J. Weeks,et al.  Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. , 2015, Clinical breast cancer.

[8]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Bonneterre,et al.  Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data , 2014, Clinical Cancer Research.

[10]  M. Rezai,et al.  Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Seshan,et al.  Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. , 2014, Human pathology.

[12]  D. Nielsen,et al.  A systematic review of bevacizumab efficacy in breast cancer. , 2014, Cancer treatment reviews.

[13]  W. Gradishar,et al.  Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. , 2014 .

[14]  G. Hortobagyi,et al.  Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Buyse,et al.  Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer , 2013 .

[16]  M. Parmar,et al.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.

[17]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[18]  T. Delozier,et al.  Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. , 2012, The Lancet. Oncology.

[19]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[20]  James A Young,et al.  Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.

[21]  M. Wicha,et al.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.

[22]  Tanja Fehm,et al.  Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells , 2012, Breast Cancer Research.

[23]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[24]  L. Frati,et al.  Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  T. Fehm,et al.  Abstract PD04-06: Changes in Circulating Tumor and Endothelial Cells in Peripheral Blood of Patients Treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study “GeparQuinto” , 2010 .

[27]  X. Pivot,et al.  Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  E. van Marck,et al.  Is there a role for mammary stem cells in inflammatory breast carcinoma? , 2010, Cancer.

[29]  T. Fehm,et al.  Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.

[30]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[31]  H. Tesch,et al.  Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[33]  Seigo Nakamura,et al.  Molecular targets for treatment of inflammatory breast cancer , 2009, Nature Reviews Clinical Oncology.

[34]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[35]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[36]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[37]  Yi Xiao,et al.  The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. , 2008, The American journal of pathology.

[38]  T. Kroll,et al.  Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Bertucci,et al.  Defining the molecular biology of inflammatory breast cancer. , 2008, Seminars in oncology.

[40]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[41]  M. Untch,et al.  The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Y. Yen,et al.  Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. , 2004, Journal of Clinical Oncology.

[44]  F. Bertucci,et al.  Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment , 2004, Bone Marrow Transplantation.

[45]  G. Hortobagyi,et al.  Paclitaxel in the multimodality treatment for inflammatory breast carcinoma , 2001, Cancer.

[46]  T. Delozier,et al.  First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial) , 1999, British Journal of Cancer.

[47]  R. Vij,et al.  Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Shpall,et al.  High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.

[50]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.